Summary & Overview
HCPCS Q4191: Restorigin per Square Centimeter, Add-On
HCPCS Level II code Q4191 identifies Restorigin billed per square centimeter as an add-on product used alongside a primary procedure. As an add-on HCPCS Level II code, Q4191 captures use of a per-square-centimeter biologic or skin substitute product applied during surgical or wound management procedures. Accurate use of this code affects billing precision, payment segmentation between primary procedures and adjunct products, and national reporting of advanced wound care utilization.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what the code represents, typical sites of service, and the clinical context for use. The publication summarizes payer coverage patterns, common billing modifiers, and related operational considerations where available. It also outlines benchmarks and policy updates relevant to add-on product coding and documentation expectations.
This national-focused brief is designed for providers, billing professionals, and policy analysts who need a practical reference for coding Restorigin per square centimeter as an adjunct to primary procedures, and for administrators tracking utilization and reimbursement implications across major payers.
Billing Code Overview
HCPCS Level II code Q4191 describes Restorigin, per square centimeter (add-on, list separately in addition to primary procedure). This code represents an add-on biologic or skin substitute product billed per square centimeter when used in conjunction with a primary surgical or wound care procedure.
Service type: Product-based wound care or surgical adjunct used to treat wounds or soft-tissue defects.
Typical site of service: Hospital inpatient or outpatient surgical settings, ambulatory surgery centers, wound care clinics, and other procedural care locations where a primary procedure is performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient with a full-thickness skin defect or a chronic nonhealing wound undergoes surgical application of a biologic dermal matrix product, billed as Q4191 per square centimeter as an add-on to a primary wound debridement or grafting procedure. Typical patients include adults with diabetic foot ulcers, venous stasis ulcers, pressure injuries, or traumatic skin loss where standard grafting is insufficient. The clinical workflow begins with preoperative assessment and optimization of comorbidities (eg, diabetes control, infection management). In the operating room or procedural suite the wound is thoroughly debrided and hemostasis achieved. The surgeon measures the wound surface area and applies the Restorigin biologic matrix to the prepared wound bed, securing it as indicated (sutures, staples, or biologic adhesives) and covering with appropriate dressings. The add-on Q4191 is reported in addition to a primary procedure code that describes the debridement, skin graft, or complex wound reconstruction. Post-procedure care includes regular dressing changes, infection surveillance, offloading if applicable, and staged reassessment for graft incorporation or need for repeat application. Typical sites of service are outpatient surgery centers, hospital outpatient departments, and inpatient operating rooms depending on patient complexity and comorbidities.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|